GNRH1 and prostate cancer: And two initial studies that demonstrated this association analyzed data from the Surveillance Epidemiology and End Results-Medicare linked database and identified an increased risk of incident coronary heart disease, myocardial infarction, and cardiovascular death among men with prostate cancer treated with a GnRH agonist (32, 33).